Asia Fresh News

Asia Fresh Stories

Archive for December 2014

Fosun to Acquire Meadowbrook Insurance Group, Inc.

leave a comment »

— Transaction Enables Fosun to Establish Significant Presence in the U.S. P&C Market

HONG KONG and SOUTHFIELD, Mich., Dec. 31, 2014 /PRNewswire/ — Fosun International Limited (HKEx stock code: 00656, together with its subsidiaries, “Fosun”) and Meadowbrook Insurance Group, Inc. (NYSE: MIG) (“Meadowbrook”), today announced that they have entered into a definitive agreement under which Fosun will acquire Meadowbrook for US$8.65 per share in cash, representing an aggregate transaction value of approximately US$433 million.

The transaction follows a thorough review of strategic alternatives by the Meadowbrook board of directors and represents a 24% premium over Meadowbrook’s closing price on December 29, 2014 and a premium of 39% to Meadowbrook’s three-month average closing price for the period ending December 29, 2014.  The transaction also represents a multiple of approximately 1.04x Meadowbrook’s tangible book value per share as of September 30, 2014.

Fosun is a leading investment group headquartered in Shanghai, China with over $50 billion in total assets and operations around the world.  The acquisition of Meadowbrook will enable Fosun to establish a significant presence in the U.S. P&C market.  Currently, Fosun has more than one third of its total assets invested in insurance businesses around the world, including investments in Yong’an P&C Insurance, Pramerica Fosun Life Insurance and Peak Reinsurance, as well as Fidelidade Group, Portugal’s largest insurance company.  Fosun’s most recent investment in the insurance sector was an acquisition of a 20% equity interest in Ironshore Inc. inAugust 2014.

Guo Guangchang, Chairman of Fosun, said, “This transaction allows Fosun to establish a presence in the important U.S. P&C market, consistent with our strategy of expanding our core insurance business.  Meadowbrook has a talented employee base, comprehensive offering of high-quality specialty insurance products, robust distribution network and a strong commitment to meeting the evolving needs of its policyholders.  The transaction represents another milestone for Fosun and will enable Fosun to further strengthen its insurance-oriented comprehensive financial capabilities.”

Robert S. Cubbin, President and Chief Executive Officer of Meadowbrook, said, “Combining with Fosun further strengthens our capital base as we continue to focus on supporting the needs of our customers, partners and policyholders, improving our underwriting performance and driving profitability.”

Mr. Cubbin continued, “This transaction is the culmination of a thorough strategic review process to maximize shareholder value.  We believe this is a positive outcome for our shareholders, who will receive significant value; our employees, who will benefit from enhanced opportunities as part of a larger, global organization; and our customers, partners and policyholders, who will benefit from an even stronger specialty risk, insurance and service provider.”

The transaction has been unanimously approved by all of the directors of the Meadowbrook board of directors present at the meeting and has been unanimously approved by the Fosun board of directors.  Following the closing of the transaction, which is expected in the second half of 2015, Meadowbrook will continue to maintain its headquarters in Southfield, Michigan and will operate under the Meadowbrook brand name.  The transaction is subject to the approval of Meadowbrook’s shareholders as well as regulatory approvals and the satisfaction of other specified closing conditions.

KPMG, Towers Watson Delaware and PricewaterhouseCoopers are acting as advisors of finance, actuary and tax, respectively, to Fosun.  DLA Piper LLP is acting as legal advisor to Fosun.  Willis Capital Markets & Advisory is acting as exclusive financial advisor and Sidley Austin LLP is acting as legal counsel to Meadowbrook in connection with the transaction.

About Fosun International Limited

Fosun was founded in 1992 in Shanghai. Fosun International Limited (00656.HK) was listed on the Main Board of The Stock Exchange of Hong Kong Limited on 16 July 2007. Today, Fosun has established four business engines comprising “insurance, industrial operations, investment and asset management”. It strives to become a world-class investment group underpinned by the twin drivers of “insurance-oriented comprehensive financial capability” and “industrial-rooted global investment capability”. It is dedicated to applying the value investing principle to its investment model of “Combining China’s Growth Momentum with Global Resources”. For more information, please visit

About Meadowbrook Insurance Group

Meadowbrook Insurance Group, Inc., based in Southfield, Michigan, is a leader in the specialty program management market. Meadowbrook includes several agencies, claims and loss prevention facilities, self-insured management organizations and six property and casualty insurance underwriting companies. Meadowbrook has twenty-eight locations in the United States. Meadowbrook is a risk management organization, specializing in specialty risk management solutions for agents, professional and trade associations, and small to medium-sized insureds. Meadowbrook Insurance Group, Inc. common shares are listed on the New York Stock Exchange under the symbol “MIG”. For further information, please visit Meadowbrook’s corporate web site

Fosun Contacts

Edith Lui / Kate Zhao
Corporate Communications & Marketing Department
(852) 2509 3228 / (1) 646 490 9835 /

Meadowbrook Contacts

For Investors:
Karen M. Spaun
SVP & Chief Financial Officer

For Media:
Bryan Locke / Jenny Gore
Sard Verbinnen & Co.

Cautionary Note Regarding Forward-Looking Statements

This communication may include certain statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding the intent, belief, or current expectations of management, including, but not limited to, those statements that use the words “believes,” “expects,” “anticipates,” “estimates,” or similar expressions.  We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of the Company, which could cause actual results to differ materially from such statements.  Risks and uncertainties relating to the proposed transaction with the Company include, but are not limited to: the risk that the Company’s shareholders do not approve the transaction; uncertainties as to the timing of the transaction; the risk that regulatory or other approvals required for the transaction are not obtained or are obtained subject to conditions that are not anticipated; competitive responses to the transaction; litigation relating to the transaction; disruptions of current plans and operations caused by the announcement and pendency of the proposed transaction; potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; disruption from the proposed transaction making it more difficult to maintain relationships with agents, wholesalers, suppliers, customers, policyholders and regulators; and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2013 filed with the U.S. Securities and Exchange Commission.

Important Additional Information

This communication is being made in respect of the proposed merger transaction involving Meadowbrook Insurance Group, Inc. (“Meadowbrook”) and Fosun International Limited. The proposed merger will be submitted to the shareholders of Meadowbrook for their consideration. In connection therewith, Meadowbrook intends to file relevant materials with the SEC, including a preliminary proxy statement and a definitive proxy statement. The definitive proxy statement will be mailed to the shareholders of Meadowbrook. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION, INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and shareholders may obtain free copies of the proxy statement, any amendments or supplements thereto and other documents containing important information about Meadowbrook, once such documents are filed with the SEC, through the website maintained by the SEC at Copies of the documents filed with the SEC by Meadowbrook will be available free of charge on Meadowbrook’s website via the investor relations section of our website at or under the heading “Documents and Filings”. Shareholders of Meadowbrook may also obtain a free copy of the definitive proxy statement by contacting Meadowbrook’s Investor Relations Contact, Karen Spaun, at +1-248-204-8178.

The Company and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Meadowbrook is set forth in its proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on April 14, 2014, its annual report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 5, 2014, and in subsequent documents filed with the SEC, each of which can be obtained free of charge from the sources indicated above. Other information regarding the participants in the proxy solicitation of the shareholders of  Meadowbrook and a description of their direct and indirect interests, by share holdings or otherwise, will be contained in the preliminary and definitive proxy statements and other relevant materials to be filed with the SEC when they become available.

Fosun International Limited
Meadowbrook Insurance Group, Inc.

Written by asiafreshnews

December 31, 2014 at 3:17 pm

Posted in Uncategorized

Alistair Capital Letter to Prudential Regulation Authority Expresses Concerns About AmTrust Financial Services, Inc.

leave a comment »

— Detailed Letter from Alistair Capital Management Explains the Need for an Investigation into Intra-Company and Related Party Reinsurance Agreements

NEW YORK, Dec. 31, 2014  /PRNewswire/ — Alistair Capital Management, L.L.C. (together with its affiliates, “Alistair Capital” or “the Firm”) today announced that Alistair Capital has delivered a letter to the Prudential Regulation Authority, a division of the Bank of England, regarding property and casualty insurer AmTrust Financial Services, Inc. (“AmTrust” or “the Company”) (NASDAQ: AFSI).

In the letter, the full text of which is available at, Alistair Capital describes why it believes AmTrust and its subsidiaries pose particular risk to the policyholders of AmTrust Europe, Ltd. and the Lloyd’s Central Fund.

Alistair Capital emphasizes that its primary concern is the counterparty risk associated with intra-company reinsurance agreements between AmTrust’s U.S., U.K., and Irish subsidiaries and AmTrust’s Bermuda-domiciled reinsurance captive, AmTrust International Insurance, Ltd. (“AII”).

In preparing its letter, Alistair Capital relied solely upon publicly available documents such as AmTrust’s filings with the Securities and Exchange Commission and similar agencies, foreign and domestic, whose materials are available online. Alistair Capital notes the conclusions expressed in its letter reflect the personal opinions of its President, Casey H. Nelson, which are based upon the materials referenced in the letter. Please be advised that as a result of its analysis and the concerns expressed in its letter, Alistair Capital Fund, L.P. maintains a short position in AmTrust common stock and owns put options on the same.

About Alistair Capital Management, L.L.C.

Alistair Capital Management, L.L.C. was founded in 2009 by Casey H. Nelson and manages Alistair Capital Fund, L.P.

Source: Alistair Capital Management, L.L.C.

Written by asiafreshnews

December 31, 2014 at 2:34 pm

Posted in Uncategorized

Growthgate Capital Successfully Sells Majority Stake in Able Logistics (UAE) to Kerry Logistics Network (HK)

leave a comment »

MANAMA, Bahrain, Dec. 30, 2014 /PRNewswire/ — Growthgate Capital, the Gulf-based investment firm announced today that it has exited from its investment in Able Logistics Group (Able) by selling its 70 percent equity stake therein to Kerry Freight Services (South Asia) Pte. Ltd., a wholly owned subsidiary of Kerry Logistics Network, for $32 million (subject to certain adjustments). Taking into account this transaction and prior dividends received, Growthgate Capital has realized a 3x returns on its investment in Able. The preparations for Able’s IPO which were announced in Q1 2014, were set aside indefinitely in favor of Kerry’s strategic buyout offer.


Able is a leading freight forwarder and logistics provider headquartered in Dubai, with additional operating bases in the Middle East and other key hubs in the Near and Far East. The transaction involved the acquisition of 70 percent of Able’s capital stock by Kerry Freight Services (South Asia). Kerry Logistics Network, the owner of Kerry Freight Services, is a publicly listed company in Hong Kong (stock code 00636) with a total market cap ofHK$20.5 billion as at December 29, 2014. Kerry is one of Asia’s major logistics providers with a global network that stretches across six continents, including an extensive distribution network and hub operations in Greater China and the ASEAN region.

Growthgate first invested in Able in 2007, when operations were limited to the UAE and few Asian destinations. Today the company operates from multiple bases in Dubai, Sharjah, Oman, Saudi Arabia, Afghanistan, and Hong Kong, with over 500 corporate customers including multinationals in diversified sectors such as electronics, food, and fast moving consumer goods. Able’s management expects to achieve $135 million in total revenues in 2014.

“We have always believed in Able’s business model, and the outstanding team led by Dr. Ghanem Al Hajri, Executive Chairman and Vijay Vikram, CEO. Since 2007, we have been continuously impressed by their commitment to delivery and the phenomenal results achieved. This is a great development for Able, as Kerry is the best strategic partner to take the company forward and give the senior management team the opportunity to propel the business on a wider scale as part of a global platform,” commented Karim A. Souaid, General Manager of Growthgate Capital.

“Since its establishment in 2001, Able has delivered consistent and outstanding growth quarter after quarter. Starting from scratch, the company has gained a significant market share of the corporate logistics and freight forwarding market in little over ten years, in a highly competitive and concentrated context, and a difficult economic climate. This tremendous success is the result of the combination of an ambitious project with a faultless execution by a great management team. We have consistently supported and funded Able, and are proud of its achievements,” added Souaid.

Vijay Vikram, CEO and co-founder of Able, said, “We have very much appreciated the steadfast support from Growthgate throughout the past years. As the only institutional investor in the company, Growthgate took the initial risk, and continued to support us ever since, committing valuable time, capital and efforts to build-up the platform in different markets and varying economic cycles. Growthgate has simply been an ideal growth partner.”

White & Case acted as international counsel for Growthgate Capital on the transaction whereby HLP LLC acted as local counsel. PwC further advised Growthgate on specific finance and accounting aspects of the transaction.

About Able Logistics

Able Logistics Group is an integrated provider of freight forwarding, land transportation, and warehousing services, and a regional leader in its business segment thanks to an extensive network than spans throughout theMiddle East and Asia; and a management team with over 35 years of experience. Since its inception in 2001, Able has evolved from an airfreight forwarder into a logistics service provider using multi-modal solutions to address the growing needs of governmental agencies; airlines, multinationals and conglomerates operating inAsia, Europe, Africa and the Middle East.

About Growthgate Capital

Growthgate Capital is a Gulf-based private investment firm that follows a “buy-and-build” strategy. The firm specializes in buying into well-managed companies with scalable business models, and leveraging those capabilities by acquiring/adding more entities to build up and grow said companies. Targets are principally selected from the GCC and other key markets of the MENA region. Growthgate Capital was formed in 2007 with$200m in permanent capital subscribed by a select group of shareholders including State-owned banks, public pension funds, and single-family offices from the Middle East.

The firm has completed to date four liquidity events including the sale of its stake in Roots Steel International (Saudi Arabia) in 2013, a partial exit from Able via a dividend recap in Q1 2014, the reverse takeover by Gama Aviation with Hangar 8 Plc and its subsequent listing on the London Stock Exchange; and the current strategic sale of Able to Kerry Logistics Networks. Growthgate Capital had, as of beginning of 2013, circa $1.65 billion in Assets-under-Monitoring and is managed by Growthgate Partners.

Contact: Sabina Lindstedt +971(0)4-3302220

Source: Growthgate Capital

Written by asiafreshnews

December 31, 2014 at 12:22 pm

Posted in Uncategorized

Avnet Successfully Concludes X-fest 2014 with Record-breaking Attendance in Asia

leave a comment »

SINGAPORE, Dec. 29, 2014 /PRNewswire/ — Avnet Electronics Marketing Asia, an operating group of Avnet, Inc. (NYSE: AVT) marked the conclusion of its hallmark event, X-fest 2014 with the last technical seminar held in Hangzhou, China after a successful six weeks run in 15 cities across Asia. More than 4,000 engineers across Asia benefitted from the practical, how-to training workshops, setting a new record-breaking attendance for the biennial seminar.

In China alone, 3,100 engineers participated in the full day seminar which featured twelve technical courses from three educational tracks: Zynq and the IoT, Design Essentials, and Techniques and Applications.

“Avnet is committed to deliver continuous technical trainings of the breeding edge technology, which have over the last 15 years, delivered immediate and practical benefits to enhance our customers’ design engineering capabilities,” said Stephen Wong, President, Avnet Electronics Marketing Asia. “The engineers who have participated in X-fest have strengthened their knowledge of how to use Zynq and FPGAs in their systems as well as to determine which software, tools, development kits and third parties IPs are available to enhance their design efforts. They have also built a better understanding of components that sit next to the SoC/FPGA, and how to integrate them in a complete system. The knowledge gained will help improve a designer’s efficiency, reduce risks and shorten their total system design cycle time.”

In addition, X-fest has also greatly enhanced the overall customer value by offering a single platform to access multiple on-site production demonstrations and reference designs exhibited by Avnet’s industry-leading partners including Xilinx, Analog Devices, STMicroelectronics, TE Connectivity, Texas Instruments, Maxim Integrated, Micron, Freescale, MathWorks, ON Semiconductor and Spansion.

“We’re thrilled to be involved in this successful program together with Avnet,” said Fai Yeung, Vice President of Xilinx APAC Sales and Marketing. “X-fest has provided a great platform for us to reach out to the design engineering community to expand their knowledge on Xilinx’s All Programmable products and to improve on design skills so as to achieve faster time-to-market of innovative devices harnessing the power.”

About Avnet Electronics Marketing Asia

Avnet Electronics Marketing, an operating group of Avnet, Inc. (NYSE: AVT), is the leading electronics component distributor in Asia. With its regional headquarters in Singapore, the company has offices in 47 locations in Asia. Avnet Electronics Marketing Asia distributes semiconductors, interconnects, passive and electromechanical components to serve a wide range of customers including original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and small- to medium-sized businesses, and provides associated design-chain and supply-chain services. More information is available at

About Avnet
Avnet, Inc. (NYSE: AVT), a Fortune 500 company, is one of the largest distributors of electronic components, computer products and embedded technology serving customers globally. Avnet accelerates its partners’ success by connecting the world’s leading technology suppliers with a broad base of customers by providing cost-effective, value-added services and solutions. For the fiscal year ended June 28, 2014, Avnet generated revenue of $27.5 billion. For more information, visit

WeChat ID: AvnetAsia

Join Avnet’s LinkedIn community

Read more about Avnet on our blog

Tan Weiwei
Avnet Electronics Marketing Asia
Deborah Wang
The Hoffman Agency China

Written by asiafreshnews

December 30, 2014 at 5:06 pm

Posted in Uncategorized

PR Newswire increases footprint in Asia Pacific with expansion into Jakarta and new office premises in Singapore

leave a comment »

-PR Newswire, the leading global provider of news distribution and multimedia platforms opens new office in Jakarta to further grow its network in Indonesia and moves its Singapore office to bigger premises with new staff hires.

HONG KONG, Dec. 24, 2014 /PRNewswire/ — With its existing Asia-Pacific network of 10 offices in key gateway cities including Hong Kong, Kuala Lumpur, Singapore, Taipei, Beijing and Shanghai, PR Newswire expanded its Asia presence with a new Jakarta office opened in October. Coupled with over a 12-year solid track record in Asia-Pacific, PR Newswire values the importance of local presence in key markets and has over 140 multifunctional on-ground staff to engage with their key audiences in the region.

“I am pleased to announce the opening of our new Jakarta office and relocation of the Singapore office. The addition of a new office underpins PR Newswire’s commitment to further drive our Asia-Pacific business in this region. We will continue to serve the communications needs of companies who seek to reach their target market — locally or internationally via our news distribution network to tell their stories to the world,” said Royce Shih, Vice President Asia-Pacific Sales & Marketing at PR Newswire.

Southeast Asia’s biggest economy

According to the Asian Development Outlook 2014 Update released in September by the Asian Development Bank, Indonesia is one of three largest economies in Asia besides China and India. It’s no surprise that Indonesia is one of the top markets in the region that is attracting inbound investment.

Immense interest in Indonesia and its business potential prompted PR Newswire to open a Jakarta office in October 2014. This strategic move will propel the efforts in building our network with local media partners and increasing brand recognition, especially among the local business community.

Next year, PR Newswire plans to issue a white paper on the Indonesian media landscape and to hold events to offer PR and content marketing related insights and trends to the local communications professionals.

Bigger premises, bigger team

According to Forbes’ “Best Countries for Business” 2014 list, Singapore is ranked #8 with a higher GDP per capita compared to most developed countries, and attracting major investments in pharmaceutical and medical technology production.

With its consistent strong economic performance, and ample business opportunities for newswire and multimedia related services, PR Newswire Singapore office will be relocated to bigger premises on December 30, 2014 to accommodate new hires. This is also a testament for PR Newswire’s commitment to increase resources to provide better support to its existing clientele in Singapore, as well as in Australia which is fully supported by dedicated sales personnel based out of Singapore office. The new office remains in Raffles Place — the heart of the CBD, but it is now located at One Raffles Place, a prominent landmark in the business district area.

The new address is as follows and will be effective from 30th December 2014:

1 Raffles Place, #20-61,
One Raffles Place Tower 2,
Singapore, 048616
Tel: +65 6233 5688
About PR Newswire:
PR Newswire ( is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, public relations officers and investor relations professionals to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry in 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia — and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world’s enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company.

Media Contacts:
Fern Cheng
Senior Marketing Manager, Asia-Pacific, ex-China

Joanna Yip
Marketing Communications Manager

Logo –

Source: PR Newswire

Written by asiafreshnews

December 30, 2014 at 3:39 pm

Posted in Uncategorized

PR Newswire Upgrades Its ReleaseWatch Report in Move to Enhance Reach of Its News Releases

leave a comment »

HONG KONG, Dec. 29, 2014 /PRNewswire/ — PR Newswire today formally rolled out its newly upgraded Asia-Pacific ReleaseWatch Report™, which includes a deep integration with PR Newswire’s expansive global database of media professionals, PR Newswire for Journalists (PRNJ). The new report provides clients with a more visual interpretation of the analysis of the media reach, diversified report formats and reporting on all language versions in which the news release was issued, enabling the client to gain an in-depth and comprehensive understanding of the effectiveness of their distribution.
PR Newswire’s newly upgraded Release Watch Report
PR Newswire’s newly upgraded Release Watch Report

A major issue confronting most PR professionals in the world of increasingly complex news communication channels is how to measure the effectiveness of a news release. According to PR Newswire’s survey report “2014 Corporate Content Communication Trends and ROI Evaluation in the Era of New Media”, 56.7% of the respondents said the media coverage and quality of the news release are the most important KPI indicators in measuring the reach while other reference indicators such as search visibility, the number of industry vertical websites and portals that post the news release as well as the visibility in social and mobile channels are all becoming progressively more important.

As a corporate newswire with 60 years of professional experience, PR Newswire has been and remains committed to helping companies and organizations achieve the most optimal results for the news releases issued through its channels. This upgraded version of the ReleaseWatch Report™ targets clients from all the countries and regions across Asia, including mainland China, Hong Kong and Taiwan. It is another important upgrade of PR Newswire in enhancing the effectiveness of news releases for clients in the Asia-Pacific region following its recent release of its Visibility Report™ (VR for short).

Highlights of this upgrade in the ReleaseWatch Report™ include:

More visual interpretation of the analysis of the media reach

The new ReleaseWatch Report™ features a deep integration with PR Newswire for Journalists (PRNJ for short), providing a visual rendering of the analysis:

a. Results of the analysis of the data are delivered by email within 24 hours of the clear time, including the number of times the release has been viewed by journalists in PRNJ so that clients can gain an intimate knowledge of the level media coverage and time at which the news release came to their attention.

b. Two diagrams provide a visual representation of the statistical analysis have been added to show the usage timeline following the issuance of the release over the subsequent 96 hour period enabling clients to see clearly the trends in terms of media pickup and display on websites as well as a graphical display showing when readership of the release peaked in relation to the clear time.

More granular display of the effectiveness

The new report is broken down into five sections in terms of presentation: search visibility, websites visibility, social visibility, mobile visibility and brand visibility. In addition, the report also shows print media pick up, as well as screenshots of the release on financial terminals such as Bloomberg.

a. In addition to Baidu and Google, the one click option of the two major Chinese search engines 360 and Sogou have been added to the search visibility section, illustrating the search visibility of the news release in real time.

b. In the websites visibility section, industry of the website displaying the news release has been added so that clients can have a quick understanding on the media coverage in different categories in one glance.

c. Social visibility displays the presentation of the news release on Weibo and provides monitoring and profiling of the Weibo distribution.

d. Mobile visibility lists the number of subscribers as well as the platform of each app in which the news release is displayed so clients can download the relevant app and see for themselves the display of the release in the app.

e. The brand visibility section is integrated with PR Newswire’s Monitoring Platform in order to monitor and collect the data on the frequency and trends of the client’s brand keywords on websites and in social media channels.

More practical report presentation format

Screenshots Report
Screenshots Report

a. The report supports multilingual fonts, with a simplified /traditional Chinese and a Chinese-English version available. More Asian languages will be added soon.

b. A comprehensive upgrade has been made to the excel report format, and a screenshots report has been added (in PDF). An HTML-formatted report supports a preview and photo save as well as downloadable website screenshots.

For more information, please contact:

Client Service Team
Tel: +852-2572-8228

We welcome you to search for our WeChat account “PR Newswire Information”, WeChat ID: PR_Newswire, or check @ PR Newswire Information on Weibo

About PR Newswire

PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, public relations officers and investor relations professionals to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry in 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content — from rich media to online video to multimedia — and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world’s enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company.

PR Newswire’s Asian website:

PR Newswire’s global website:

Media Contacts:

Fern Cheng
Senior Marketing Manager, Asia-Pacific, ex-China

Joanna Yip
Marketing Communications Manager

Photo –
Photo –
Logo –

Written by asiafreshnews

December 30, 2014 at 3:26 pm

Posted in Uncategorized

OneSimCard Now Available on Malaysia Airlines

leave a comment »

BOSTON, Dec. 30, 2014 /PRNewswire/ — OneSimCard, a leading global provider of low cost international mobile roaming services for businesses and leisure travelers, announced today that Malaysia Airlines has begun offering OneSimCard during in-flight duty free sales. OneSimCard has partnered with Malaysia Airlines’ Temptations Magazine Team and Inflight Sales Group to offer Malaysia Airlines’ customers OneSimCards on international flights.

Standard international roaming rates offered by the major telecoms carriers are exorbitantly high. On average, international roamers should expect to pay over US $2.50 per minute for both incoming and outgoing voice calls. Major telecom carriers also charge international roamers extremely high internet data rates, often in excess of US$10.00 per MB.

OneSimCard offers international travelers an average discount of about 85% off the voice, text messaging and internet data roaming rates offered by major telecoms carriers. OneSimCard customers enjoy FREE incoming calls in 160+ countries and outgoing international roaming calls beginning at US $0.25 per minute. Internet Data rates begin at US$0.13 per MB. OneSimCard comes with both a European and US mobile phone number, with additional phone numbers available in 65+ countries.

OneSimCard works worldwide in unlocked GSM devices and phones. The user simply replaces their domestic carriers’ SIM card with OneSimCard when traveling internationally. All users can replace their own SIM cards in just a few seconds. OneSimCard provides international roaming services in over 200 countries. OneSimCard is a pre-paid service which does not require any contract and has no connection fees, subscription fees or monthly maintenance fees.

To learn more about OneSimCard please go to:

About OneSimCard
OneSimCard (, a division of Belmont Telecom, Inc., is a leading provider of mobile service for international travelers offering low-cost voice, text and data service worldwide. OneSimCard saves travelers 85% on international roaming charges compared to their regular domestic mobile carrier and has been widely acclaimed by mobile industry and travel experts, including those from The New York Times, Washington Post, Boston Globe and PC Magazine.

Source: OneSimCard

Written by asiafreshnews

December 30, 2014 at 2:45 pm

Posted in Uncategorized

Jean Boulle Group Reports Successful First Clinical Trial Implant of the Tendyne Transcatheter Mitral Valve

leave a comment »

LUXEMBOURG, Dec. 30, 2014 /PRNewswire/ — Boulle Medtech Ltd, a Jean Boulle Group company focusing on medical technology and a founding investor of Tendyne Holdings, Inc. (“Tendyne”), is pleased to announce that the Tendyne Transcatheter Mitral Valve Implant (TMVI) was successfully placed in the first patient enrolled in a three-continent, multicenter trial being conducted as part of the Tendyne Feasibility Study. The study is to generate insight into the safety and performance of the Tendyne device in inoperable patients suffering from mitral regurgitation.

Drs. David Muller and Paul Jansz performed the procedure at St. Vincent’s Hospital in Sydney, Australia. Tendyne reports that the device was implanted transapically without cardiopulmonary bypass, performed as intended by completely eliminating mitral regurgitation, and that the patient was released from the hospital on day 5. Prior to this, the Tendyne device had been successfully implanted in London in three other persons under a compassionate use protocol in October and early November 2014 (see Boulle Medtech release of December 10, 2014).

The Tendyne TMVI is a fully retrievable and repositionable, apically tethered tri-leaflet porcine pericardial valve sewn onto a Nitinol (nickel/titanium) frame specifically designed to address the mitral anatomy of functional, degenerative and mixed etiology mitral regurgitation. Left untreated, mitral regurgitation can lead to heart failure and death.

About Boulle Medtech Ltd.

Boulle Medtech Ltd. is a Jean Boulle Group company focusing on medical technology. Its holdings include Tendyne Holdings, Inc. Boulle Medtech is a founding investor and major shareholder of Tendyne.

About Tendyne Holdings, Inc.

Tendyne Holdings, Inc is headquartered in Roseville, Minnesota and is a privately-held, clinical stage medical device company developing a unique Transcatheter Mitral Valve Implant (TMVI). Implanted in a beating heart in a hybrid operating room, the Tendyne design has proprietary and patented features that can treat a variety of mitral pathologies. With a less invasive approach than open cardiac surgery, TMVI may result in similar outcomes with fewer surgical complications.

For more information about the Jean Boulle Group or Boulle Medtech, contact Audrey Richardson at +352-222-512,, or go to our website

For more information about Tendyne, go to

Source: Jean Boulle Group

Written by asiafreshnews

December 30, 2014 at 12:16 pm

Posted in Uncategorized

Janssen Announces Collaboration with Gilead to Develop PREZISTA(R)-based Single-tablet Regimen for the Treatment of People Living with HIV

leave a comment »

CORK, Ireland, Dec. 29, 2014 /PRNewswire/ —

— Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union —

Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. This new STR contains a combination of darunavir (PREZISTA®), cobicistat (TYBOST®), emtricitabine and tenofovir alafenamide (TAF). A number of Phase 1 and 2 studies of the new STR have been completed. Under this amended agreement, Janssen will conduct all further clinical development of the regimen and, subject to regulatory approval, will be responsible for all manufacturing, registration, distribution and commercialization of the product worldwide.


If successfully developed and approved by regulatory authorities, this treatment would represent the first protease inhibitor-based STR and thereby continue Janssen’s commitment to providing its HIV products in more simplified dosing presentations.

“Janssen has vast experience in developing and making innovative HIV treatments available to patients and we have engaged in several successful collaborations with Gilead. We are proud to be extending our collaboration and leading the development of this darunavir-based single-tablet regimen,” says Paul Stoffels, Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Our ultimate goal is to offer new treatment options for people living with HIV. If approved, this STR has the potential to provide additional choice in the form of another one pill, once a day, as a new and simplified regimen.”

In addition to this collaboration, Janssen and Gilead have also expanded a separate agreement initiated in 2009 regarding the approved single-tablet regimen, COMPLERA®, marketed as EVIPLERA® in the European Union (EU) (rilpivirine, tenofovir disoproxil fumarate (TDF) and emtricitabine). This expanded agreement will allow for Gilead’s investigational tenofovir alafenamide (TAF), a novel nucleotide reverse transcriptase inhibitor, to replace TDF within COMPLERA®/ EVIPLERA®. TAF has been shown in clinical trials to have a better renal and bone safety profile than TDF.[1] Gilead will be responsible for the development and commercialization in most countries, while Janssen will lead the commercialization in select markets.

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[2] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[2],[3],[4]




PREZISTA® (darunavir), coadministered with ritonavir (PREZISTA®/r), and with other antiretroviral agents (ARVs), is indicated for the treatment of human immunodeficiency virus (HIV-1) infection.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 controlled Phase 3 trials of 48 weeks duration in ARV treatment-naïve and treatment-experienced patients and 2 controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.

In treatment-experienced adult patients, the following points should be considered when initiating therapy with PREZISTA®/r:

  • Treatment history and, when available, genotypic or phenotypic testing should guide the use of PREZISTA®/r
  • The use of other active agents with PREZISTA®/r is associated with a greater likelihood of treatment response

Important Safety Information

PREZISTA® (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors.

PREZISTA® is always taken with and at the same time as ritonavir (Norvir®), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA® should also be taken with food.

  • The use of other medicines active against HIV in combination with PREZISTA®/ritonavir (Norvir®) may increase your ability to fight HIV. Your healthcare professional will work with you to find the right combination of HIV medicines
  • It is important that you remain under the care of your healthcare professional during treatment with PREZISTA®

PREZISTA® does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA®.

Please read Important Safety Information below, and talk to your healthcare professional to learn if PREZISTA® is right for you.

Important Safety Information

What is the most important information I should know about PREZISTA®?

  • PREZISTA® can interact with other medicines and cause serious side effects. See “Who should not take PREZISTA®?”
  • PREZISTA® may cause liver problems. Some people taking PREZISTA®, together with Norvir® (ritonavir), have developed liver problems which may be life-threatening. Your healthcare professional should do blood tests before and during your combination treatment with PREZISTA®. If you have chronic hepatitis B or C infection, your healthcare professional should check your blood tests more often because you have an increased chance of developing liver problems
  • Tell your healthcare professional if you have any of these signs and symptoms of liver problems: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale colored stools (bowel movements), nausea, vomiting, pain or tenderness on your right side below your ribs, or loss of appetite
  • PREZISTA® may cause a severe or life-threatening skin reaction or rash. Sometimes these skin reactions and skin rashes can become severe and require treatment in a hospital. You should call your healthcare professional immediately if you develop a rash. However, stop taking PREZISTA® and ritonavir combination treatment and call your healthcare professional immediately if you develop any skin changes with these symptoms: fever, tiredness, muscle or joint pain, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes, like “pink eye.” Rash occurred more often in patients taking PREZISTA® and raltegravir together than with either drug separately, but was generally mild

Who should not take PREZISTA®?

  • Do not take PREZISTA® if you are taking the following medicines: alfuzosin (Uroxatral®), dihydroergotamine (D.H.E.45®, Embolex®, Migranal®), ergonovine, ergotamine (Cafergot®, Ergomar®), methylergonovine, cisapride (Propulsid®), pimozide (Orap®), oral midazolam, triazolam (Halcion®), the herbal supplement St. John’s wort (Hypericum perforatum), lovastatin (Mevacor®, Altoprev®, Advicor®), simvastatin (Zocor®, Simcor®, Vytorin®), rifampin (Rifadin®, Rifater®, Rifamate®, Rimactane®), sildenafil (Revatio®) when used to treat pulmonary arterial hypertension, indinavir (Crixivan®), lopinavir/ritonavir (Kaletra®), saquinavir (Invirase®), boceprevir (Victrelis™), or telaprevir (Incivek™)
  • Before taking PREZISTA®, tell your healthcare professional if you are taking sildenafil (Viagra®, Revatio®), vardenafil (Levitra®, Staxyn®), tadalafil (Cialis®, Adcirca®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), or colchicine (Colcrys®, Col-Probenecid®). Tell your healthcare professional if you are taking estrogen-based contraceptives (birth control). PREZISTA® might reduce the effectiveness of estrogen-based contraceptives. You must take additional precautions for birth control, such as condoms

This is not a complete list of medicines. Be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

What should I tell my doctor before I take PREZISTA®?

  • Before taking PREZISTA®, tell your healthcare professional if you have any medical conditions, including liver problems (including hepatitis B or C), allergy to sulfa medicines, diabetes, or hemophilia
  • Tell your healthcare professional if you are pregnant or planning to become pregnant, or are breastfeeding
  • The effects of PREZISTA® on pregnant women or their unborn babies are not known. You and your healthcare professional will need to decide if taking PREZISTA® is right for you
  • Do not breastfeed. It is not known if PREZISTA® can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV should not breastfeed because HIV can be passed to your baby in the breast milk

What are the possible side effects of PREZISTA®?

  • High blood sugar, diabetes or worsening of diabetes, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines, including PREZISTA®
  • Changes in body fat have been seen in some patients taking HIV medicines, including PREZISTA®. The cause and long-term health effects of these conditions are not known at this time
  • Changes in your immune system can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden
  • The most common side effects related to taking PREZISTA® include diarrhea, nausea, rash, headache, stomach pain, and vomiting. This is not a complete list of all possible side effects. If you experience these or other side effects, talk to your healthcare professional. Do not stop taking PREZISTA® or any other medicines without first talking to your healthcare professional

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please refer to the ritonavir (Norvir®) Product Information (PI and PPI) for additional information on precautionary measures.

Please see full Product Information for more details:

About Janssen Pharmaceutical Companies of Johnson & Johnson

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 including regarding product development.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: challenges inherent in new product development, including obtaining regulatory approvals;  competition, including technological advances, new products and patents attained by competitors; changes to regulations and domestic and foreign health care reforms; and general industry conditions, including trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission.  Copies of these filings are available online at, or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.

  1. Sax P, Brar I, Elion R, et al. 48 Week study of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF), each in a single tablet regimen with elvitegravir, cobicistat, and emtricitabine for initial HIV treatment. 53rd ICAAC. September 10-13, 2013. Denver. Abstract H1464d.
  2. World Health Organization. Global summary of the AIDS epidemic. Available at: Last accessed July 2014.
  3. Hui Dy. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42(2):81-92.
  4. World Health Organization. Global summary of the AIDS epidemic. Available at: Last accessed July 2014.


Daniel De Schryver

Ronan Collins

Stan Panasewicz

Louise Mehrotra

Source: Janssen R&D Ireland Ltd

Written by asiafreshnews

December 30, 2014 at 10:38 am

Posted in Uncategorized

Huawei Malaysia Hosts its 2014 Service Partner Conference

leave a comment »

-A move calling for closer collaborations with to serve Malaysian customers better

KUALA LUMPUR, Malaysia, Dec. 22, 2014 /PRNewswrie/ —  December 19, 2014, Huawei held its Malaysia Service Partner Conference 2014 at Impiana KLCC Hotel, Kuala Lumpur. The theme of this year’s conference was “Better Service, Embrace the Future”. The service conference aimed at awarding service partners who have provided high quality delivery services, surpassed engineer skill development benchmarks, and contributed significantly to service solution revenue in the past 12 months. This event also served as a great networking platform for the partners to share their experiences and to gain a better understanding of Huawei’s service solutions and policies, as well as training programs to achieve growth together.

CEO of Huawei Malaysia, Abraham Liu welcomes service partners to Huawei Malaysia Service Partner Conference 2014
CEO of Huawei Malaysia, Abraham Liu welcomes service partners to Huawei Malaysia Service Partner Conference 2014

Huawei Malaysia Chief Executive Officer Abraham Liu opened the conference with a welcome speech that thanked all the service partners for their support and highlighted their contribution to the great progress of Huawei’s Enterprise Business in Malaysia over the years. He said, “Local network strength and capabilities are instrumental for business growth in a B2B environment. Over the last few years, our focus has been on strengthening these relationships as well as the structure, tools and processes around them in order to build a win-win business environment.

The Malaysian market is one of the most important markets within Huawei’s Southern Pacific region expansion plans. We appreciate the contribution of our service partners towards this end. We are happy to say our partners in Malaysia share our passion and enthusiasm for top-notch service and business transformation through technology. It is only through collaboration with our partners that we are able to build a complete service platform, provide on-time and accurate technical support and high quality training programs to meet and exceed the high expectations our customers have of us.”

The top three service partners that received awards in the conference are Whizzwork Sdn Bhd, Global Forway Sdn Bhd and Netaxis Sdn Bhd.

Mr. Guan Swee Teng, Managing Director of Netaxis Sdn Bhd, said, “The collaboration with Huawei was not an easy start. Our engineers were not familiar with Huawei products and there was little reference material available. However, thanks to Huawei’s Channel Enablement program and the Support-E system, the transition is more seamless now. We are confident that we will continue to grow together with Huawei in the coming years.”

Mr. Nagiswaren, Senior Solution Manager of Global Forway Sdn Bhd, who was one of the award recipients, said, “We see a lot of potential in our partnership with Huawei Enterprise. Various training classes and hands-on trainings, such as Huawei’s Certified Network Associate course, have helped us in developing engineering skills within our organization. Looking ahead, we would certainly like to achieve a greater success together with Huawei.”

Feng Bao Shuai, Vice President of Huawei Southern Pacific, Service Department, said, “We all know that service plays an instrumental role in any successful ICT business; it is the basis for us to gain a foothold in the market. Good service relies on people, tools, processes and a whole support system. We appreciate the support and suggestions that the partners have given to Huawei. We are focused on continued collaboration, tools and strategies in order to empower our channel ecosystem to achieve their goals. Enterprise business is a very dynamic space, marked by new trends and technologies and a hyper-growth trajectory. It is only through developing a healthy channel ecosystem that Huawei and partners can provide top of the line service to customers and embrace future opportunities.”

For more information, please logon to

About Huawei

Huawei is a leading global information and communications technology (ICT) solutions provider with the vision to enrich life through communication. Driven by customer-centric innovation and open partnerships, Huawei has established an end-to-end ICT solutions portfolio that gives our customers competitive advantages in telecom and enterprise networks, devices and cloud computing. Huawei’s 150,000 employees worldwide are committed to creating maximum value for telecom operators, enterprises and consumers. Our innovative ICT solutions, products and services have been deployed in over 170 countries and regions, serving more than one third of the world’s population. Founded in 1987, Huawei is a private company fully owned by its employees.

For more information, please visit Huawei online: or follow us on:

Photo –

Source: Huawei
Related Links:

Written by asiafreshnews

December 29, 2014 at 5:44 pm

Posted in Uncategorized